Brief: Paratek Pharmaceuticals Posts Q3 Loss Per Share $0.46
05/11/2020 22:01
Nov 5 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2020 TOTAL
REVENUE OF $13.7 MILLION
* Q3 LOSS PER SHARE $0.46
* Q3 REVENUE $13.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF
$11.9
MILLION
* Q3 EARNINGS PER SHARE ESTIMATE $-0.61 -- REFINITIV IBES
DATA
* NOW ANTICIPATES FULL YEAR 2020 TOTAL REVENUE TO BE AT
HIGHER END
OF PREVIOUSLY COMMUNICATED RANGE OF $78 TO $83 MILLION
* LOWERING 2020 RESEARCH AND DEVELOPMENT AND SG&A EXPENSE
GUIDANCE
TO APPROXIMATELY $120 MILLION
* ANTICIPATE EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES WILL PROVIDE FOR A CASH RUNWAY THROUGH END OF 2023
Source text for Eikon: ID:nGNXFknvY
Further company coverage: PRTK.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million